S erious cardiovascular disease (CVD) and particularly sudden cardiac death (SCD) in a young
person, including an athlete, is a rare, but tragic event with far-reaching implications for families and communities (2, 3) . Families who are directly affected by these relatively rare events struggle to comprehend why more effective screening strategies are not routine and standardized in most of the Westernized World, including the United States and Europe. Besides the devastating blow to the families involved, these tragic events are also devastating to the community, which often calls for more vigorous screening of athletes, regardless of the cost.
However, the incidence of SCD among young athletes is vigorously debated, with wide estimates ranging from 1 per 3,000 athlete-years (AY) in National Collegiate Athlete Association (NCAA) Division I (DI) male basketball athletes to as low 1 per 919,000 AY reported in Minnesota high school athletes, a difference of >300-fold (3) (4) (5) . The wide range of reported incidence is largely due to the study methodology. An accurate incidence requires a precise numerator (cases identified) and denominator (population studied). Studies with mandatory reporting and known populations report higher incidence rates than those examining media reports or estimating denominators. In addition, inclusion criteria differ between studies, with some studies including only SCD while exercising, some including SCD at any time, and some including both sudden cardiac arrest (SCA) and SCD. Moreover, emerging evidence demonstrates a much higher incidence of SCD in some Dr. Lavie has reported that he has no relationships relevant to the contents of this paper to disclose. per significant CVD diagnosis using the Seattle and refined criteria, respectively (10) . Clearly, the cost of SCD prevention would likely be considerably higher.
Nevertheless, these investigators suggest that more contemporary ECG interpretation criteria will reduce costs and improve cost-effectiveness, which may make this testing more cost-permissive, at least for some sporting organizations.
Although the incidence of SCA/SCD is debated, the prevalence of CVD in young people is about 1 in 300 (11) . Clearly, ECG significantly increases the likelihood of detecting CVD; however, the very high falsepositive rates in the past made its use impractical.
This study demonstrated dramatically reduced false positive rates using modern criteria to interpret the ECG (to 4.3%) (10) . This study did not compare the cost per diagnosis of H&P to H&P with ECG or ECG alone, perhaps because in this cohort, the H&P did not diagnose any of the potentially lethal CVDs. This finding is similar to a recent meta-analysis of 47,000 athletes, which found that ECG had a sensitivity/specificity for CVD of 94%/93%, whereas history had a sensitivity/ specificity of 20%/94% and physical examination of 9%/97% (12). Obviously, H&P have extremely low sensitivities as supported in the present study.
This study demonstrates that ECG screening and appropriate secondary testing can potentially be accomplished cost-effectively to identify CVD (10).
The current U.S. recommendation of screening with
H&P is the least cost-efficient manner to identify CVD because of its poor sensitivity. Perhaps, a "one size fits all" model for PPE may not be appropriate.
Potentially, screening strategies should be tailored 
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